Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Discover why Regeneron Pharmaceuticals, Inc.'s Q3 earnings impress, fueled by Dupixent growth and a robust pipeline. Click ...
StockStory.org on MSN

REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery ...

In the U.S., the generic name for Libtayo in its approved indications is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance ...

Regeneron targets $7B in U.S. manufacturing investment as R&D and commercial launches accelerate

Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...

Regeneron tops quarterly estimates, plans to resubmit Eylea application

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
GlobalData on MSN

FDA approves Regeneron’s Libtayo for high-risk CSCC post-surgery

The US Food and Drug Administration (FDA) has granted approval to Regeneron Pharmaceuticals’ fully human monoclonal antibody Libtayo (cemiplimab-rwlc) as an adjuvant therapy for adults with cutaneous ...
Medscape

EMA Backs New Checkpoint Inhibitor for High-Risk Skin Cancer

The decision follows phase 3 trial data showing the immunotherapy cut disease recurrence or death risk by 68% in patients ...
Fierce Biotech

BioNTech fades out further work with cancer vaccine prospect in late-stage melanoma setting

BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...

Regeneron beats quarterly estimates on strong demand for Dupixent

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...
Dermatology Advisor

FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC

The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.
Business Insider

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of ...

Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: ...
Monthly Prescribing Reference

Libtayo Cleared for Frontline Use in Advanced NSCLC With High PD-L1 Expression

Results demonstrated that treatment with Libtayo reduced the risk of death by 32% compared with chemotherapy. The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial ...